Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

Tiziana Life Sciences (NASDAQ:TLSA) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. Zacks Research raised Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. BTIG Research reiterated a “buy” rating on shares of Tiziana Life Sciences in a report on Tuesday, September 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, August 26th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Tiziana Life Sciences Stock Performance

Tiziana Life Sciences stock opened at $1.12 on Friday. The business’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.17. Tiziana Life Sciences has a fifty-two week low of $0.76 and a fifty-two week high of $2.33.

Insider Activity

In related news, CEO Ivor Elrifi bought 667,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $1.00 per share, for a total transaction of $667,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at $4,472,261. This represents a 17.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders bought 988,423 shares of company stock valued at $985,909. Insiders own 39.82% of the company’s stock.

Institutional Trading of Tiziana Life Sciences

An institutional investor recently bought a new position in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. purchased a new stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 323,240 shares of the company’s stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned 0.25% of Tiziana Life Sciences at the end of the most recent quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.